middle.news
Orthocell’s Remplir™ Accelerates in Prostate Surgery, Eyes $2B U.S. Market
9:11am on Thursday 20th of November, 2025 AEDT
•
Healthcare
Read Story
Orthocell’s Remplir™ Accelerates in Prostate Surgery, Eyes $2B U.S. Market
9:11am on Thursday 20th of November, 2025 AEDT
Key Points
Approximately 100 nerve-sparing prostate surgeries performed with Remplir™ in Australia
Potential to expand U.S. total addressable market from $1.6 billion to $2 billion
No further FDA approvals required for U.S. launch
Over 4,000 Remplir™ units shipped to the U.S. with initial surgical cases underway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Orthocell (ASX:OCC)
OPEN ARTICLE